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Abstract 
Objectives: American College of Rheumatology (ACR)/ European League Against 
Rheumatism (EULAR) Boolean remission in rheumatoid arthritis (RA) is frequently not 
obtained solely due to a patient global assessment (PGA) >1/10 (a condition often designated 
as near-remission). This study aimed to assess which domains of impact could explain 
elevated PGA in near-remission patients. 
Methods: Ancillary analysis of data from three cross-sectional studies in patients with 
established RA. Three disease activity states were defined: remission (tender and swollen 
joint counts, C-Reactive Protein and PGA all ≤1), near-remission (idem but PGA>1) and non-
remission. Physical and psychological domains were assessed using the RA Impact of Disease 
(RAID: 0-10 numeric rating scales) as explanatory factors of PGA. Univariable and 
multivariable linear regression analyses were performed to explain PGA.  
Results: 1588 patients (79.1% females) were analysed. Mean (standard deviation) disease 
duration was 13.0 (9.8) years and 28-joint Disease Activity Score (DAS28-4v) was 3.2 (1.4). 
Near-remission [mean PGA=3.6 (1.9)] was more frequent (19.1%) than remission (12.3%). 
Scores of disease impact RAID domains were similar in near-remission and non-remission 
patients. In near-remission, PGA was explained (R2adjusted=0.55) by pain (β=0.29), function 
(β=0.23), physical wellbeing (β=0.19) and fatigue (β=0.15).  
Conclusion: Near-remission was more frequent than remission. These patients, despite having 
no signs of significant inflammation, report an impact of disease similar to the non-remission 
patients. PGA in near-remission seems to be driven by physical rather than psychological 
domains. Selecting the best therapy for these patients requires a better understanding of the 
meaning of PGA, both globally and in individual patients.  
Key Words: Rheumatoid arthritis, patient global assessment, patient reported outcomes, 
disease activity, remission, near-remission, psychological distress, psychological factors, 
outcomes, disease impact. 
Drivers of PGA in RA near-remission 
 3 
Introduction 
Disease remission (or at least low disease activity) is the therapeutic target for patients 
with rheumatoid arthritis (RA) in current treatment recommendations [1, 2]. Remission is 
defined according to the American College of Rheumatology (ACR) /European League 
Against Rheumatism (EULAR) criteria [3], which, in the Boolean-based definition require 
that tender joint count of 28 joints (TJC28), swollen joint count (SJC28), C-Reactive Protein 
(CRP, in mg/dl), and patient global assessment (PGA, 0–10 scale) are all ≤1.  
The condition where patients fail to reach remission solely because of PGA has been 
designated as "near-remission" [4]. These patients have no signs of significant joint 
inflammation since joint counts and CRP are ≤1 but evaluate their disease (using PGA) above 
1/10. In published studies, 21%-31% of RA patients were in near-remission [4-6]. Following 
current treatment recommendations [1, 2] this state of near-remission could justify 
reinforcement of immunosuppressive therapy. However, this may not be the best choice if the 
reason for not achieving remission is not inflammatory activity. In these cases, "adjuvant" 
therapies, such as analgesics, antidepressants or self-management programs might be more 
appropriate. To select the most adequate intervention in such cases, it is essential to 
understand why patients without signs of significant inflammatory activity do not achieve a 
PGA ≤1.  
In RA patients, PGA appears to be not only influenced by RA disease activity, but also 
by sociodemographic features, country/culture, psychological factors, and comorbidities, with 
emphasis on fibromyalgia [7]. However, no data are available on the meaning of PGA in the 
specific condition of near-remission.  
The aims of this study were to assess which domains of impact may explain the 
elevated PGA in near-remission patients, and to assess which domains of health better 
discriminate between disease activity states. 
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Patients and methods 
Study design and setting 
This was an ancillary analysis of three studies of patients with established RA: i) 
baseline data from the Rheumatoid Arthritis Impact of Disease (RAID) elaboration database 
[8], an international (12 European countries) observational study in 2008-2009; ii) baseline 
data from COMEDRA [9], a French multicentre clinical trial in 2011; iii) and CoimbRA 
(Coimbra Rheumatoid Arthritis cohort), a Portuguese, cross-sectional observational study in 
2015 [10].  
 
Participants 
 In all three studies consecutive adult patients were included if they had definite RA 
(ACR 1987 revised criteria or ACR/EULAR 2010 classification criteria) and were able to 
complete questionnaires. For COMEDRA, additional inclusion criteria were: age limit of 80 
years, a stable disease (for at least 3 months), and having no planned surgery in the 6 months 
following study baseline. Written consent was obtained according to the declaration of 
Helsinki for all studies, as well as approval from ethical committees, as previously reported 
[8-10].Here, patients were analysed if they had RAID [8] and remission components available 
[3].  
 
Patient global assessment 
 PGA was assessed in the three studies using the same formulation[3] - “Considering 
all the ways your arthritis has affected you, how do you feel your arthritis is today?", using 
either a 0-100 visual analogue scale (VAS) or a 0-10 numeric rating scale (NRS) (in 
COMEDRA).  
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Remission definitions 
Four different Boolean-based concepts of remission were used in this study: a) the 
ACR/EULAR Boolean remission (TJC28, SJC28, CRP mg/dl, and PGA all ≤1) [3], b) near-
remission (TJC28, SJC28, and CRP mg/dl all ≤1; and PGA>1), c) non-remission (TJC28 or 
SJC28 or CRP mg/dl >1, irrespective of PGA), and d) "3variable (3v)-remission" [11] 
(TJC28, SJC28, and CRP mg/dl all ≤1; PGA excluded from consideration).  
 
Explanatory factors of PGA 
 The seven domains of the RAID score [8] were used as possible factors to explain 
PGA: i.e., physical (pain, function, and physical wellbeing), psychological (emotional 
wellbeing and coping/self-efficacy), and mixed domains (fatigue and sleep) [12]. Each 
domain is assessed by a NRS, ranging from 0 (no impact) to 10 (high impact).  
 
Other data collection 
Age, gender, disease duration, current biologic agent (yes/no), health assessment 
questionnaire (HAQ), physician global assessment (PhGA) and 28-joint Disease Activity 
Score with 4 variables (DAS28-4v) were also assessed for patient's characterization. 
 
Statistical analyses 
Descriptive analyses, Student’s t-test to compare disease activity states and Hedges' g 
effect size (ES) were performed using IBM® SPSS® Statistics version 20.0 software. 
The ES assessed the discriminant capacity of impact domains to distinguish the 
disease activity states. To determine the drivers of PGA in near-remission patients, 
univariable (Pearson's correlation coefficient) and multivariable analyses (linear regression, 
backward method) were used. 
 
Drivers of PGA in RA near-remission 
 6 
Results 
Patient characteristics 
The evaluable population comprised 1588 patients (RAID=348; COMEDRA=936; 
CoimbRA=304), who presented typical established RA, with long disease duration (Table 1). 
Patients from COMEDRA and RAID were often treated with biologic disease modifying 
drugs (74.7% and 50.0%, respectively). Disease activity was on average, low in COMEDRA 
and in CoimbRA and moderate in RAID (Table 1). All aspects of disease impact presented 
mean values around 3.5 on 0-10 scales, except for fatigue (mean=4.3, standard deviation, 
SD=2.8) where higher numbers reflect worst status (Table 1).  
 
Remission rates and PGA cut-offs 
ACR/EULAR Boolean-based remission was achieved by only 195 (12.3%) patients 
(6.0% in RAID, 15.6% in COMEDRA and 9.2% in CoimbRA). Overall, 303 (19.1%) patients 
were in near-remission (14.4% in RAID, 14.6% in COMEDRA and 38.2% in CoimbRA). 
Near-remission was at least as frequent as remission (COMEDRA) and up to four times more 
frequent (CoimbRA). Overall, 498 (31.4%) of all patients had no signs of inflammation as 
currently assessed, i.e. were in 3v-remission (Table 1).  
In the near-remission group (n=303), mean PGA was considerably above the 
ACR/EULAR Boolean cut-off of ≤1 (mean=3.6, SD=1.9), with 70.3% and 43.9% of patients 
having a score above 2 and 3, respectively (Supplementary Figure S1).  
 
Impact domains according to disease activity states  
 Table 2 presents disease impact domains according to remission status. In non-
remission patients (n=1090), all the disease impact domains had mean values above 3.4, with 
coping, sleep, and emotional wellbeing scoring lower/better than physical domains. 
Conversely, in remission patients (n=195), only fatigue (mean=1.3) and physical wellbeing 
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(mean=1.1) presented means >1.  
Mean values of disease impact measures were very similar for patients in near-
remission and in non-remission, except (p<0.05) for pain, physical wellbeing and function 
domains (Table 2). 
Mean scores of disease impact measures were markedly different between patients in 
remission and those in near-remission (p<0.001 in all cases) (Table 2). These two groups are 
brought together under the concept of 3v-remission, whose values of disease impact are, as 
expected, in-between the two (Table 2 and Supplementary Table S1). 
 
Drivers of PGA in near-remission patients  
 In the 303 near-remission patients, PGA presented moderate (rp=0.47, emotional 
wellbeing) to good (rp=0.68, pain) correlation with disease impact domains (all p<0.001) 
(Supplementary Table S2). In multivariable analysis, PGA was explained (R2adjusted=0.55) by 
pain (β=0.29), function (β=0.23), physical wellbeing (β=0.19) and fatigue (β=0.15).  
 
Main drivers of differences of impact between disease activity states  
 Although both remission and near-remission patients had SJC28, TJC28 and CRP ≤1, 
all mean values of impact domains were statistically higher in near-remission (Supplementary 
Figure S2). Within these, physical and mixed domains of impact (pain, physical wellbeing, 
function and fatigue) presented greater effect sizes (around 1.53) than psychological ones 
(still with high effect sizes >1.0). The same trend was found for comparisons between other 
disease activity groups but with lower effect sizes (Supplementary Figure S2). Global scores 
(PGA and RAID score) were better discriminants than individual RAID domains only when 
comparing remission with near-remission patients (Supplementary Figure S2). 
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Discussion 
Several important findings emerged from this first study exploring disease impact in 
different Boolean disease activity states. It was confirmed that ACR/EULAR Boolean-based 
remission is very stringent (12.3% of all patients). Near-remission, i.e., failing to reach 
remission solely due to PGA, was at least as frequent as, and up to four times more frequent 
than remission. Because of the influence of PGA, the percentage of patients classified as in 
remission was reduced from 31.4% (3v-remission) to 12.3%. The scores of the diverse 
domains of impact in near-remission patients were similar to patients in non-remission and 
PGA was high in these patients (mean=3.6) Pain, physical wellbeing, function and fatigue 
were the impact domains that better differentiated remission from near-remission states. 
These results were confirmed by multivariable analyses, supporting the conclusion that high 
PGA in near-remission patients is driven by physical factors (which might represent 
subclinical inflammatory activity) and does not especially reflect psychological aspects 
including anxiety or distress, or fibromyalgia, contradicting common beliefs [7, 13]. 
 
 This study has strengths and weaknesses. A weakness may be the relatively low 
percentage of patients in remission, which might limit the power. Using different 
multicultural cohorts imposes some cautions in the interpretation of results. However, it 
allowed a greater sample and permitted to analyse multicultural differences in PGA and its 
impact on the classification of remission. How PGA is measured and its relatively "unclear" 
cut-offs and formulations are another issue [7]. Using the same formulation in the three 
studies strengthened this pooled analysis. Some relevant comorbidities such as fibromyalgia, 
depression, or radiological damage were not assessed, although psychological distress and 
function were assessed through the RAID questionnaire [8]. Further studies might explore 
their influence on PGA. Finally, other measures of quality of life than the RAID would have 
strengthened the paper.  
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One recent study explored PGA determinants in different levels of disease activity 
[14], but using tertiles of Disease Activity Score (DAS28) instead of remission [3], and the 
small sample rendered assessment of remission not feasible and a DAS28<4.2 was adopted.  
The ratio of near-remission versus remission rates was variable between studies, from 
1/1 to 4/1 patients. Possible reasons to explain this difference could include culture, which 
may affect PROs [15]. Other reasons could be differences in the provision of patient 
education, psychological support, and patient expectations between countries. Near-remission 
rate differences could also be affected by reliability of joint counts [16]. SJC and TJC may 
miss subclinical inflammation in joints [17], and totally ignores inflammation in other 
structures, such as tenosynovitis, which the patients can still perceive and value. The use of 
ultrasound [18] or sensitive CRP measurement [19] rather then current methods should be 
further explored, specially in patients in near-remission.  
 As expected, patients in remission had a low disease impact. Fatigue was, among this 
group of patients and also among all, the domain with highest mean score, underlining its 
importance in the impact of RA, even in patients in remission [20].  
 
The findings reported herein have important implications for clinical practice. Patients 
in near-remission presented high levels of symptoms with mean scores around 3.5. Although 
a higher cut-off for PGA in the definition of remission would certainly increase the number of 
remissions, it would not make clinical sense in patients whose high PGA is not related to 
residual inflammation but to structural damage, or an unrelated comorbidity, such as 
osteoarthritis, depression or fibromyalgia. Such patients would require adjunctive tailored 
interventions (e.g. patient education, physiotherapy, analgesics, antidepressants, or cognitive 
behavioural therapy) and not the reinforcement of disease-modifying medication 
recommended to those not achieving remission. Such special requirements are briefly 
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addressed in the EULAR recommendations, which state: "once any patient has reached a low 
disease activity that is close to remission, the individual disease activity variables have to be 
considered in detail before major therapeutic changes are made." [1]. However, no specific 
guidance is given for such cases. Another important issue is when to stop or taper 
immunosuppression – is the target then remission or also near-remission? The present results 
support the idea that PGA poses problems when used in the 'combined' definition of 
remission. Perhaps having two separate definitions of remission: one for the purposes of 
defining the target of immunosuppressive therapy (excluding PGA) and another patient-
based, would make sense.  
The impact of disease from the patient’s perspective should continue to be taken very 
seriously, but this would be better served by an instrument that allows the identification of the 
specific cause of persistent impact and thus, guide adjunctive therapy. The RAID [8], taking 
its individual dimensions separately, may well be a good solution to this need. 
 
Key messages:  
– Boolean remission in rheumatoid arthritis (RA) is very stringent (achieved by only 6.0% 
to 15.6% of patients) whereas 14.4 to 38.2% of patients failed to reach remission solely 
because of patient global assessment (PGA) >1 (near-remission). 
– Near-remission patients reported high disease impact, similar to the non-remission 
patients, indicating that absence of signs of inflammation does not equate to full 
abrogation of disease impact as reflected by current measures. 
– High PGA in near-remission patients did not reflect more the psychological aspects than 
the physical aspects of impact as reported by patients. 
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